Purple biotech issues letter to shareholders

Rehovot, israel, feb. 04, 2022 (globe newswire) -- purple biotech ltd. ("purple biotech", or the "company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, is pleased to issue the following letter from its chief executive officer, isaac israel, to its shareholders.

PPBT Ratings Summary

PPBT Quant Ranking